Aurora Cannabis Announces $100M ATM Offering and Strategic Divestiture of Bevo Agtech Interest
ACB sits 18% above its 52-week low of $3.422.
Summary
Aurora Cannabis announced a new U.S. $100 million ATM equity program and a strategic agreement to divest its controlling interest in Bevo Agtech Inc., alongside reporting a net loss and ongoing internal control weaknesses.
Key Events · Financing and Capital Events · ACB
-
Establishes U.S. $100 Million At-The-Market Equity Program
The company filed a prospectus supplement to establish a new ATM program, allowing it to issue and sell up to U.S. $100 million of common shares. Proceeds are intended for strategic and accretive purposes, including increased cultivation capacity and potential M&A.
-
Strategic Divestiture of Bevo Agtech Interest
Aurora entered into a definitive agreement to exchange its common shares of Bevo Agtech Inc. for preferred shares, effectively divesting its controlling interest in the plant propagation segment. This transaction will lead to Bevo's financial results being presented as discontinued operations and includes a transfer of shareholder loans for $5.5 million in cash.
-
Reports Net Loss and Impairment Charges
For the three months ended December 31, 2025, the company reported a net loss of $1.9 million. It also recognized $31.9 million in impairment charges for intangible assets and goodwill during the nine months ended December 31, 2025, primarily affecting its Australian Cannabis and Plant Propagation CGUs.
-
Exiting Lower-Margin Canadian Consumer Markets
Aurora plans to exit certain lower-margin consumer segments in Canada to prioritize its higher-margin global medical cannabis business, expecting improved consolidated adjusted gross margins and lower adjusted SG&A in future quarters.
Analysis · ACB · Life Sciences
Aurora Cannabis has announced a new At-The-Market (ATM) equity program to raise up to U.S. $100 million, which represents a substantial potential dilution given the company's market capitalization. This capital raise is intended for strategic purposes, including cultivation capacity and potential M&A. Concurrently, the company is undergoing a significant strategic restructuring by agreeing to exchange its controlling common share interest in Bevo Agtech Inc. for preferred shares. This move effectively divests the plant propagation segment, which had been experiencing operational challenges and covenant non-compliance, allowing Aurora to focus on its core, higher-margin global medical cannabis business. The Bevo transaction will result in Bevo's financial results being reclassified as discontinued operations. The company also reported a net loss of $1.9 million for the quarter and recognized $31.9 million in impairment charges related to intangible assets and goodwill, primarily in its Australian Cannabis and Plant Propagation segments. Additionally, material weaknesses in internal controls over financial reporting continue to be disclosed.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACB was trading at $4.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $230.2M. The 52-week trading range was $3.42 to $6.91. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.